Last update 26 Jun 2024

Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)

Overview

Basic Info

Drug Type
T-lymphocyte cell therapy
Synonyms
allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2), Herpes simplex virus thymidine kinase (HSV-Tk) donor lymphocytes, HSV-Tk
+ [5]
Target-
Mechanism
Cell replacements, Immunostimulants
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhaseWithdrawn
Regulation-
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hematologic Neoplasms
EU
18 Aug 2016
Hematologic Neoplasms
IS
18 Aug 2016
Hematologic Neoplasms
LI
18 Aug 2016
Hematologic Neoplasms
NO
18 Aug 2016
Hematopoietic stem cell transplantation
EU
18 Aug 2016
Hematopoietic stem cell transplantation
IS
18 Aug 2016
Hematopoietic stem cell transplantation
LI
18 Aug 2016
Hematopoietic stem cell transplantation
NO
18 Aug 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
TK-DLI
eazhsnmtjg(kgobbyfqch) = yzphrtgxtb qmkqnkzrrq (ikvcgxgxlb )
-
20 Jun 2006
Not Applicable
8
Tk-DLI
opxltapfyt(doawzbyehz) = Multiple doses of ganciclovir (10 mg/kg/die), in the absence of immunosuppressive drugs, quickly resulted in the complete resolution of all signs of GvHD jcubetthlb (wkwrmigogw )
-
15 Jul 2004
Not Applicable
8
yfzbxaxymf(ufqnuizfaw) = 1/8 patients experienced grade II biopsy-proven acute GvHD, involving the skin and the liver. The administration of multiple doses of ganciclovir (10 mg/kg/die), in the absence of immunosuppressive drugs, quickly resulted in the complete resolution of all clinical and biochemical signs of GvHD. Two patients of this series received unmodified DLI and died of refractory GvHD and disease progression. wccrmledzo (jdpzaeelas )
Positive
01 May 2002
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free